Información del producto
- EMD-61753
- Asimadoline [INN]
- Benzeneacetamide, N-((1S)-2-((3S)-3-hydroxy-1-pyrrolidinyl)-1-phenylethyl)-N-methyl-alpha-phenyl-
- Benzeneacetamide, N-(2-(3-hydroxy-1-pyrrolidinyl)-1-phenylethyl)-N-methyl-alpha-phenyl-, (S-(R*,R*))-
- Benzeneacetamide, N-[(1S)-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-1-phenylethyl]-N-methyl-α-phenyl-
- Benzeneacetamide, N-[2-(3-hydroxy-1-pyrrolidinyl)-1-phenylethyl]-N-methyl-α-phenyl-, [S-(R*,R*)]-
- Emd 61753
- N-((alpha S)-alpha-((3S)-3-Hydroxy-1-pyrrolidinyl)methyl)benzyl)-N-methyl-2,2-diphenylacetamide
- N-((alphaS)-alpha-(((3S)-3-Hydroxy-1-pyrrolidinyl)methyl)benzyl)-N-methyl-2,2-diphenylacetamide
- N-[(1S)-2-[(3S)-3-Hydroxy-1-pyrrolidinyl]-1-phenylethyl]-N-methyl-α-phenylbenzeneacetamide
- Ver más sinónimos
- N-{(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl}-N-methyl-2,2-diphenylacetamide
- Unii-D0Vk52Nv5M
Asimadoline (EMD-61753) is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis. Asimadoline is an orally administered agent that acts as a kappa opioid receptor agonist. It has shown encouraging clinical efficacy for the treatment of IBS in a barostat study in IBS patients and has the potential for treating other gastrointestinal diseases.
Propiedades químicas
Consulta técnica sobre: TM-T4633 Asimadoline
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.